FDA Appoints Dr. George Tidmarsh as New Head of the Center for Drug Evaluation and Research
The FDA has appointed Dr. George Tidmarsh as the new head of the Center for Drug Evaluation and Research, bringing over 30 years of expertise in medicine and drug development to enhance public health safety and innovation.
On July 23, 2025, the U.S. Food and Drug Administration announced the appointment of Dr. George Francis Tidmarsh, M.D., Ph.D., as the new director of the Center for Drug Evaluation and Research (CDER). This pivotal role involves overseeing the safety, efficacy, and regulatory approval of a wide range of pharmaceuticals, including over-the-counter medications, prescription drugs, biologics, and generics, ensuring they meet stringent standards to protect public health.
Dr. Tidmarsh is a distinguished medical professional with a deep background in both clinical medicine and scientific research. He earned his Ph.D. in cancer biology from Stanford University, where he also completed residency training in pediatrics, along with subspecialty training in pediatric oncology and neonatology. With over 30 years of experience spanning biotechnology, medicine, and regulatory science, he is well-equipped to lead the agency's efforts in fostering pharmaceutical innovation and safety.
The FDA Commissioner, Marty Makary, M.D., M.P.H., praised Dr. Tidmarsh, highlighting his extensive experience as a physician-scientist and his comprehensive knowledge of the drug development process—from laboratory research to clinical application. His leadership is expected to enhance the FDA's drug review programs and promote initiatives that improve healthcare outcomes in the United States.
In addition to his regulatory role, Dr. Tidmarsh co-founded Stanford University's Master of Translational Research and Applied Medicine program, aimed at converting scientific discoveries into practical medical solutions. Throughout his career, he has contributed to the development of seven FDA-approved drugs and held leadership positions in various biopharmaceutical companies. His work focuses on advancing therapies for unmet medical needs while ensuring rigorous safety standards.
This appointment marks a significant milestone for the FDA, as it seeks to strengthen its role in ensuring safe drug access and fostering biomedical innovation.
For more information, visit FDA official announcement.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Texas Declares End to Measles Outbreak After Months of Spread
Texas has declared the end of its recent measles outbreak after more than 42 days without new cases, emphasizing the importance of vaccination and public health efforts in controlling highly contagious diseases.
Udenafil Shows Promising Results in Improving Exercise Capacity in Fontan Patients with Reduced Baseline Function
A post-hoc analysis of the FUEL trial reveals that udenafil significantly improves exercise capacity in Fontan patients with reduced baseline function, offering promising avenues for targeted therapy.
Correctional Officers' Perspectives on Harm-Reduction Strategies in Prisons
Exploring correctional officers' attitudes towards harm-reduction services in prisons reveals barriers and opportunities to improve inmate health and safety through supportive strategies.
Innovative Diagnostic Test Promises Early Detection and Improved Treatment for Leptospirosis
A new diagnostic method developed by Yale researchers enables early detection of leptospirosis through identifying leptospiral VM proteins, promising better treatment options and improved global health management.